Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biological Efficacy and Toxicity of Diamidines in Myotonic Dystrophy Type 1 Models

23 Jun 2015

Abstract excerpt

Myotonic dystrophy type 1 (DM1) is a disease characterized by errors in alternative splicing, or "mis-splicing". The causative agent of mis-splicing in DM1 is an inherited CTG repeat expansion located in the 3' untranslated region of the DM protein kinase gene. When transcribed, CUG repeat expansion RNA sequesters muscleblind-like (MBNL) proteins, which constitute an important family of alternative splicing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy and Myosin Studies
Share to Fungal and yeast genetics research
Share to Genetic Neurodegenerative Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26103061
DOI: 10.1021/acs.jmedchem.5b00356

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological Efficacy and Toxicity of Diamidines in Myotonic Dystrophy Type 1 ModelsPMID 26103061Read ↗

Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screeningSemantic proximity Read ↗

Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple MechanismsSemantic proximity Read ↗

Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1Semantic proximity Read ↗

The Dimeric Form of 1,3‐Diaminoisoquinoline Derivative Rescued the Mis‐splicing of Atp2a1 and Clcn1 Genes in Myotonic Dystrophy Type 1 Mouse ModelSemantic proximity Read ↗

Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophySemantic proximity Read ↗

Therapeutics development in myotonic dystrophy type 1Semantic proximity Read ↗

Myotonic dystrophy: candidate small molecule therapeuticsSemantic proximity Read ↗

Targeting Toxic RNAs that Cause Myotonic Dystrophy Type 1 (DM1) with a Bisamidinium InhibitorSemantic proximity Read ↗

AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1Semantic proximity Read ↗

Co-opting MBNL-dependent alternative splicing cassette exons to control gene therapy in myotonic dystrophySemantic proximity Read ↗

Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse ModelSemantic proximity Read ↗

A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.